- |||||||||| ranolazine ER / Generic mfg.
Review, Journal: The role of coronary microcirculation in heart failure with preserved ejection fraction: An unceasing odyssey. (Pubmed Central) - Dec 14, 2024
Additionally, patients affected by both conditions may be facing an adverse prognosis. Finally, there is limited evidence suggesting a beneficial effect of renin-angiotensin-aldosterone system blockers, ranolazine, and sodium-glucose cotransporter-2 inhibitors in CMD, with further evidence being awaited regarding the impact of other pharmacotherapies such as anti-inflammatory agents.
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: Exploring the Effects of Tomatidine ((3?, 5?, 22?, and 25?)-Spirosolan-3-ol) on Voltage-gated Na+ currents: Insights Into Its Ionic Mechanisms of Action on Current Magnitude, Gating, and Frequency Dependence. (Pubmed Central) - Dec 6, 2024
During a train of depolarizing pulses, tomatidine slowed the exponential decay of INa (T), and this effect was reversed by Ran or dapagliflozin...In neuro-2a cells, tomatidine increased INa (T) amplitude and slowed its inactivation, with this effect being attenuated by Ran or CBZ. In conclusion, tomatidine enhanced magnitude and modified its gating behaviors.
- |||||||||| Review, Journal: Stable Angina Pectoris: A Review of Pathophysiology, Diagnosis, and Its Management. (Pubmed Central) - Nov 20, 2024
Antianginal treatment options are categorized as first line (calcium channel blockers (CCBs), ?-blockers, and short-acting nitrates) and second line (ivabradine, nicorandil, ranolazine, and trimetazidine) drugs. This review discusses different CCBs (dihydropyridines (DHPs) or nondihydropyridines) for the management of angina pectoris.
- |||||||||| ranolazine ER / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: REACT: Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy (clinicaltrials.gov) - Nov 15, 2024
P2, N=4, Terminated,
This review discusses different CCBs (dihydropyridines (DHPs) or nondihydropyridines) for the management of angina pectoris. N=16 --> 4 | Trial completion date: Dec 2025 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Jun 2025 --> Apr 2024; Low accrual and subject engagement
- |||||||||| ranolazine ER / Generic mfg.
Journal: Eco-friendly hydrotropic spectrophotometric analysis of ranolazine hydrochloride. (Pubmed Central) - Nov 13, 2024
ICR patients with a CTO had more frequent hospitalizations for ischemia and myocardial infarctions compared with those without. The lowest limits of RAN.HCl that could be accurately detected and quantified were 0.0016 and 0.0049, 0.0018 and 0.0055, 0.0058 and 0.0176, 0.0024 and 0.0075, 0.0074 and 0.0224, 0.0021 and 0.0064
- |||||||||| ranolazine ER / Generic mfg.
Journal: Ranolazine in chronic total occlusion percutaneous coronary intervention. (Pubmed Central) - Oct 4, 2024
We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).
- |||||||||| ranolazine ER / Generic mfg.
Review, Journal: Ranolazine Unveiled: Rediscovering an Old Solution in a New Light. (Pubmed Central) - Sep 14, 2024
Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine's mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.
- |||||||||| Review, Journal: Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers. (Pubmed Central) - Sep 8, 2024
We conclude that there is strong variance in the pharmacological effects of these drugs, and in the available information. At present, GS967 and riluzole can be regarded bona fide INaP blockers, while phenytoin and lacosamide are blockers that only act on the slowly inactivating component of sodium currents.
- |||||||||| famotidine / Generic mfg.
Preclinical, Journal: Neuroprotective Effect of Famotidine in Mouse Models of Alzheimer's Disease. (Pubmed Central) - Aug 28, 2024
Despite the heterogeneity in the currently available data, ranolazine appears to be an effective and safe option for the management of various arrhythmias. Famotidine and its combination at prescribed doses in the current study improved learning and memory impairments in mice model of Alzheimer's disease probably via their antioxidant and anti-inflammatory properties confirmed by a significant increase in antioxidant mediator and a significant decrease in oxidative stress marker and inflammatory cytokines.
- |||||||||| ranolazine ER / Generic mfg.
Trial initiation date, HEOR: A Study of Ranolazine in ALS (clinicaltrials.gov) - Aug 13, 2024
P2, N=72, Not yet recruiting,
Famotidine and its combination at prescribed doses in the current study improved learning and memory impairments in mice model of Alzheimer's disease probably via their antioxidant and anti-inflammatory properties confirmed by a significant increase in antioxidant mediator and a significant decrease in oxidative stress marker and inflammatory cytokines. Initiation date: Jul 2024 --> Dec 2024
- |||||||||| diltiazem / Generic mfg., sotalol / Generic mfg., ranolazine ER / Generic mfg.
Journal, Adverse drug reaction: DREAMER: Exploring Common Mechanisms of Adverse Drug Reactions and Disease Phenotypes through Network-Based Analysis. (Pubmed Central) - Aug 2, 2024
We further demonstrate the application of DREAMER in drug repurposing and propose sotalol (targeting KCNH2), ranolazine (targeting SCN5A, currently under clinical trial), and diltiazem (indicated drug targeting CACNA1C and SCN3A) as candidate drugs to be repurposed for cardiac arrest. In summary, DREAMER effectively detects molecular mechanisms underlying phenotypes emphasizing the importance of network-based analyses with integrative data for enhancing drug safety and accelerating the discovery of novel therapeutic strategies.
- |||||||||| ranolazine ER / Generic mfg.
New P2 trial, HEOR: A Study of Ranolazine in ALS (clinicaltrials.gov) - Jul 29, 2024
P2, N=72, Not yet recruiting,
- |||||||||| ranolazine ER / Generic mfg.
Preclinical, Journal: Ranolazine Ameliorates T1DM-Induced Testicular Dysfunction in Rats; Role of NF-?B/TXNIP/GSDMD-N/IL-18/Beclin-1 Signaling Pathway. (Pubmed Central) - Jul 1, 2024
Although ranolazine exhibited a reduction in inflammation as seen by lower expression of nuclear factor-?B (NF-?B) and cluster of differentiation (CD68) in the testicles, these biochemical findings were validated by improvements in the morphological and histopathological outcomes of both the pancreatic and testicular tissues. In conclusion, daily oral administration of ranolazine (40 and 80 mg/kg) for 8 weeks could be a promising therapy for T1DM-induced testicular dysfunction through its dose-dependent anti-oxidant and anti-inflammatory effects.
- |||||||||| ranolazine ER / Generic mfg.
Chronic coronary syndrome (CCS): the journey so far and the road to the future (Dublin; Online) - Jun 13, 2024 - Abstract #ESC2024ESC_6714;
To discuss the importance of close follow-up and shared decision making to enhance the quality of care for CCS patients. To review the clinical data for ranolazine, a selective inhibitor of the late sodium current.
- |||||||||| Journal: Triazole antifungal drug interactions-practical considerations for excellent prescribing. (Pubmed Central) - Jun 2, 2024
We highlight interactions with drugs used in children and new agents introduced for the treatment of haematological malignancies or graft versus host disease (midostaurin, ibrutinib, ruxolitinib and venetoclax). We also summarize the multiple interactions between oral and inhaled corticosteroids and triazole antifungals, and the strategies needed to optimize the therapeutic benefits of triazole antifungal therapy while minimizing potential harm to patients.
- |||||||||| ranolazine ER / Generic mfg.
Preclinical, Journal: 1,4-Disubstituted Piperazin-2-Ones as Selective Late Sodium Current Inhibitors with QT Interval Shortening Properties in Isolated Rabbit Hearts. (Pubmed Central) - May 17, 2024
To overcome the drawbacks, e.g., low efficacy and inhibition effect on K+ current, of the FDA-approved late INa inhibitor ranolazine, chain amide 6a-6q, 1,4-disubstituted piperazin-2-ones 7a-7s, and their derivatives 8a-8n were successively designed, synthesized, and evaluated in vitro on the NaV1.5-transfected HEK293T cells by the whole-cell patch clamp recording assay at the concentration of 40 ?M...It exhibited low hERG inhibition and was able to reverse the ATX-II-induced augmentation of late INa phenotype of LQT3 model in isolated rabbit hearts. These results suggest the application potentials of 7d in the treatments of arrhythmias related to the enhancement of late INa.
- |||||||||| ranolazine ER / Generic mfg.
Review, Journal, Metastases: Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels. (Pubmed Central) - Apr 29, 2024
This association could contribute to explain the benefits of the drug in patients with CCS. Ranolazine, alone or in combination with appropriate therapies, could be reformulated as a safe anti-metastatic drug offering many potential advantages over current systemic treatment modalities.
- |||||||||| Myrbetriq (mirabegron) / Astellas, Winrevair (sotatercept) / BMS, Merck (MSD)
Review, Journal: Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension. (Pubmed Central) - Apr 1, 2024
Discovering novel therapeutic and antiarrhythmic strategies may be challenging for further research. Undoubtedly, such research should include protection of the heart from inflammation and oxidative stress, as these are primary pro-arrhythmic factors that jeopardize cardiac Cx43 homeostasis, the integrity of intercalated disk and extracellular matrix, and, thereby, heart function.
- |||||||||| verapamil / Generic mfg., pimozide / Generic mfg., ranolazine ER / Generic mfg.
Journal: Human induced pluripotent stem cell-derived closed-loop cardiac tissue for drug assessment. (Pubmed Central) - Feb 9, 2024
Moreover, these cells showcased diminished sensitivity to verapamil and maintained low arrhythmia rates with ranolazine-two drugs associated with a low risk of torsades de pointes (TdP). Notably, the TW group displayed increased arrhythmia rates with high and intermediate risk TdP drugs (quinidine and pimozide), underscoring the potential utility of this system in drug assessment applications.
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal, Adverse events: Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. (Pubmed Central) - Feb 7, 2024
The review encompasses the underlying molecular and cellular mechanisms of cardiotoxicity, associated risk factors, and diagnostic methods. Additionally, we provide information on several available treatments and drug choices for angina resulting from 5-FU exposure, including nicorandil, ranolazine, trimetazidine, ivabradine, and sacubitril-valsartan, which have demonstrated potential in mitigating or protecting against chemotherapy-induced adverse cardiac effects.
- |||||||||| Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
Retrospective data, Review, Journal: Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis. (Pubmed Central) - Feb 7, 2024
Additionally, we provide information on several available treatments and drug choices for angina resulting from 5-FU exposure, including nicorandil, ranolazine, trimetazidine, ivabradine, and sacubitril-valsartan, which have demonstrated potential in mitigating or protecting against chemotherapy-induced adverse cardiac effects. Among guideline-recommended antidysrhythmic drugs, the combination of digoxin IV and amiodarone IV is definitely among the least safe for cardioversion of recent onset AF; flecainide, vernakalant, ibutilide, propafenone, and amiodarone IV are definitely among the most effective for cardioversion within 4
- |||||||||| hyoscine butylbromide oral / Generic mfg., ranolazine ER / Generic mfg.
Preclinical, Journal: Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia. (Pubmed Central) - Feb 7, 2024
The majority of pyramidal neurons had large vesicular nuclei with prominent nucleoli and appeared to be more or less normal, reflecting the all-beneficial effects of Rn when the hippocampal tissue was examined under a microscope. Our findings indicated that Rn, through its antioxidative, anti-inflammatory, and anti-apoptotic effects, as well as the control of the expression of GFAP, BDNF, and Tau proteins, has a novel neuroprotective impact against scopolamine-induced dementia in rats.
- |||||||||| ranolazine ER / Generic mfg.
Journal: Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention. (Pubmed Central) - Jan 27, 2024
The ranolazine group showed (A) significantly lower troponin I level increases compared to the control group for up to 24 h, (B) significantly lower CPK levels after 4, 10, and 24 h compared to the preconditioning group (p = 0.020, p = 0.020, and p = 0.019, respectively) and significantly lower CPK levels compared to the control group after 10 h (p = 0.050), and (C) significantly lower CK-MB levels after 10 h compared to the control group (p = 0.050). This study suggests that combining RIPC before scheduled coronary procedures with ranolazine pretreatment may be linked to reduced ischemia induction, as evidenced by lower myocardial enzyme levels.
- |||||||||| ACC Young Scholars (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_8089;
Cardiac medications that have known interactions with colchicine include diltiazem, verapamil, amiodarone, carvedilol, ranolazine, and statins. Knowledge of dosing considerations, including drug interactions and renal and hepatic dose adjustments, can help to reduce the risk of toxicity.
- |||||||||| UNRAVELING VASOSPASTIC ANGINA: A CASE OF DIAGNOSTIC INTRICACIES (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6783;
Our case of vasospastic angina highlights the vital role of invasive diagnostics in navigating complex and intermittent presentations. Provocative testing not only unravels the intricacies of this condition but also showcases its pivotal role in enhancing diagnostic precision and has been shown to improve quality of life and angina symptoms.
- |||||||||| ranolazine ER / Generic mfg.
RANOLAZINE-INDUCED BRASH SYNDROME: A CASE REPORT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_828;
Treatment often requires interventions such as temporary pacemaker placement and hemodialysis. Rapid recognition and proper management are crucial to reduce mortality.
- |||||||||| ranolazine ER / Generic mfg.
Journal, Surgery: The Anti-Apoptotic Effect of Ranolazine on Cerebral Protection during Cardiopulmonary Bypass and Carotid Artery Surgery. (Pubmed Central) - Jan 24, 2024
Malondialdehyde (Group 3: p = 0.003, Group 4: p = 0.009), reduced glutathione (Group 4: p = 0.04), acid phosphatase (Group 3: p = 0.04), noradrenaline (Group 3: p = 0.01), and Bcl-2 (Group 4: p = 0.004) levels were significantly higher in the Rn-treated groups. The results of this study demonstrated the antiapoptotic effect of Rn in a brain ischemia-reperfusion model of rats receiving Rn before the procedure.
- |||||||||| ranolazine ER / Generic mfg.
Trial completion, Enrollment change: Impact of Ranolazine on Coronary Microcirculatory Resistance (clinicaltrials.gov) - Dec 26, 2023
P=N/A, N=7, Completed,
The results of this study demonstrated the antiapoptotic effect of Rn in a brain ischemia-reperfusion model of rats receiving Rn before the procedure. Unknown status --> Completed | N=20 --> 7
- |||||||||| Review, Journal: Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes. (Pubmed Central) - Dec 10, 2023
However, ranolazine, in addition to symptom relief properties, is an antianginal drug showing favorable effects in decreasing the arrhythmic burden and in ameliorating the glycemic profile of these patients. In this review, we summarize the available data regarding the antianginal and pleiotropic effects of this drug.
- |||||||||| ranolazine ER / Generic mfg.
Journal: Anti-inflammatory reprogramming of microglia cells by metabolic modulators to counteract neurodegeneration; a new role for Ranolazine. (Pubmed Central) - Nov 27, 2023
We also demonstrated the synergistic anti-inflammatory effect of Quercetin and Idebenone, and the ability of Ranolazine, Quercetin and Naringenin to counteract the neurotoxic effect of LPS-activated microglia on 661W neuronal cells. Overall, these data suggest that using the selected molecules -also in combination therapies- might represent a valuable approach to reduce inflammation and neurodegeneration while avoiding long term side effects of corticosteroids.
- |||||||||| ranolazine ER / Generic mfg.
Review, Journal: The Role of Ranolazine in Heart Failure-Current Concepts. (Pubmed Central) - Nov 13, 2023
Ranolazine's therapeutic mechanisms in myocardial ion channels and energy utilization are documented in patients with chronic coronary syndromes. Nevertheless, ranolazine might have a broader effect in the therapy of heart failure and further mechanistic research is required.
- |||||||||| Tectin (tetrodotoxin) / CK Life Sci
Retrospective data, Journal, Metastases: Effect of Voltage-Gated Sodium Channel Inhibitors on the Metastatic Behavior of Prostate Cancer Cells: A Meta-Analysis. (Pubmed Central) - Nov 12, 2023
In experiments using licensed inhibitors Lamotrigine, Oxcarbazepine, Phenytoin, Ranolazine, Riluzole and Lidocaine, the g value was 1.37 (95 % CI = 2.02-0.71)...<b></b> Meta-analysis confirmed that VGSCs are an enhancing factor in the metastasis of PCa cells. The VGSCs appear to be an important target in the diagnosis and development of new treatment options in PCa.
- |||||||||| ranolazine ER / Generic mfg.
Journal: ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial. (Pubmed Central) - Oct 31, 2023
Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.
- |||||||||| ranolazine ER / Generic mfg.
Journal: Improvement of Vascular Insulin Sensitivity by Ranolazine. (Pubmed Central) - Sep 13, 2023
In conclusion, RN facilitated the vasodilator effects of IN, both direct and induced, on the adrenergic system. Therefore, RN increases vascular sensitivity to IN, thus decreasing tissue resistance to the hormone, a key mechanism in the development of type II diabetes.
|
